TrialCancer science2022

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.

Masaki Ri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.